Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers
- 1 January 2002
- journal article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 41 (2) , 137-152
- https://doi.org/10.2165/00003088-200241020-00005
Abstract
To compare the pharmacokinetic and pharmacodynamic characteristics of angiotensin II receptor antagonists as a therapeutic class.Keywords
This publication has 49 references indexed in Scilit:
- Distinction between surmountable and insurmountable selective AT1receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1receptorsBritish Journal of Pharmacology, 1999
- Angiotensin II antagonism and plasma radioreceptor‐kinetics of candesartan in manBritish Journal of Clinical Pharmacology, 1998
- Lack of Effect of Food on the Oral Bioavailability of Irbesartan in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1998
- Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor AntagonistsClinical Pharmacokinetics, 1997
- Losartan PotassiumDrugs, 1996
- Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspectsJournal Of Hypertension, 1995
- Effects of Losartan on a Background of Hydrochlorothiazide in Patients With HypertensionHypertension, 1995
- Characterization of the Angiotensin II Receptor Antagonist TCV-116 in Healthy VolunteersHypertension, 1995
- Concentration-Effect Analysis of Antihypertensive Drug ResponseClinical Pharmacokinetics, 1994
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993